- Home
- CTO vs AUTL Comparison
CTO vs AUTL Comparison
Compare CTO & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CTO | AUTL |
|---|---|---|
| Founded | 1902 | 2014 |
| Country | United States | United Kingdom |
| Employees | 42 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 599.1M | 407.2M |
| IPO Year | N/A | 2025 |
Fundamental Metrics
Financial Performance| Metric | CTO | AUTL |
|---|---|---|
| Price | $20.39 | $1.73 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $22.50 | $8.50 |
| AVG Volume (30 Days) | 320.7K | ★ 1.6M |
| Earning Date | 04-28-2026 | 05-14-2026 |
| Dividend Yield | ★ 7.44% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,120,000.00 |
| Revenue This Year | $7.63 | $80.32 |
| Revenue Next Year | $2.76 | $53.96 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 496.00 |
| 52 Week Low | $15.07 | $1.18 |
| 52 Week High | $20.90 | $2.70 |
Technical Indicators
Market Signals| Indicator | CTO | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 55.53 | 57.71 |
| Support Level | $19.22 | $1.27 |
| Resistance Level | $20.67 | $1.73 |
| Average True Range (ATR) | 0.37 | 0.13 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 54.92 | 55.76 |
Price Performance
Historical ComparisonAbout CTO CTO Realty Growth Inc.
CTO Realty Growth Inc is a real estate investment trust company, that owns income properties in diversified markets in the United States. The company operates in four primary business segments: Income properties, management services, commercial loans and investments, and real estate operations. It derives maximum revenue from Income Properties.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.